Robert Popovian, PharmDChief Science Policy Officer, Global Healthy Living Foundation
Senior Fellow of Health Policy, Progressive Policy Institute
Visiting Health Policy Fellow, Pioneer Institute for Public Policy Research.
Anti-competitive practices and a lack of transparency in the generic drug market allow pharmacy benefit managers to profit off patients and payers.
Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Once a COVID-19 vaccine is developed, achieving universal immunization will require a cohesive, multi-faceted vaccination strategy across the U.S. healthcare system.